Safety and Efficacy of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Cohort Study

Bimekizumab is effective for the treatment of HS in real-world clinical practice, with a manageable safety profile over the 24-week period. Our findings are consistent with those reported in phase 3 clinical trials.

Authors

Institutions

Publication Details

Journal
Actas Dermo-Sifiliográficas
Published
2025-12-06
DOI
https://doi.org/10.1016/j.ad.2025.104531
Primary Topic
Hidradenitis Suppurativa and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and Efficacy of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Cohort Study

Javier Pascual-Ramírez, Ramón García Ruiz, María Matellanes‐Palacios, Pablo Fernández‐Crehuet et al.
Actas Dermo-Sifiliográficas
Hidradenitis Suppurativa and Treatments
article

Safety and Efficacy of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Cohort Study

Javier Pascual-Ramírez, Ramón García Ruiz, María Matellanes‐Palacios, Pablo Fernández‐Crehuet, C. Ciudad‐Blanco, J.M. Segura-Palacios, Gemma Martín‐Ezquerra, Carlos Cuenca‐Barrales, Eva Vilarrasa, M.L. Fernández‐Díaz, Patricia Garbayo‐Salmons, Clara Ureña Paniego, Daniel Martıń-Torregrosa, Daniel Falkenhain‐López, A. Agustí‐Mejías, Fernando Alfageme, Laura Mahiques-Santos, Martí Pons Benavent, Alejandro Molina‐Leyva, Maria García-Gil, Begoña Escutia‐Muñoz, A. Martorell, Miguel Mansilla‐Polo, Cristina Albanell‐Fernández, Enrico Giorgio Morales-Tedone, Francisca Rausell‐Félix, R Alcalá-García, R. Botella-Estrada, M.T. López-Villaescusa, N No-Pérez, N Naranjo-Guerrero, Á Estenaga-Pérez
article en

Abstract

Bimekizumab is effective for the treatment of HS in real-world clinical practice, with a manageable safety profile over the 24-week period. Our findings are consistent with those reported in phase 3 clinical trials.

Actas Dermo-SifiliográficasVol. 117(3)
University of Alicante (ES), Hospital de Sant Pau (ES), University Hospital Complex Of Vigo (ES), Hospital General Universitario Gregorio Marañón (ES), Hospital Costa del Sol (ES), Hospital Clínico Universitario de Valencia (ES), Hospital Universitario de Gran Canaria Doctor Negrín (ES), Hospital Universitario 12 De Octubre (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Hospital Obispo Polanco (ES), Hospital Universitario Virgen de las Nieves (ES), Hospital de Manises (ES), Hospital Universitario Reina Sofía (ES), Hospital de Sabadell (ES), Hospital General Universitari de Castelló (ES), Hospital Universitario Doctor Peset (ES), Hospital Del Mar (ES), Hospital de Sagunto (ES), Clinica Universidad de Navarra (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Complexo Hospitalario Universitario A Coruña (ES), Hospital Universitario Lucus Augusti (ES), Complejo Hospitalario Universitario de Albacete (ES), Hospital Virgen de los Lirios (ES), Instituto de Investigación Sanitaria La Fe (ES)
Openalex Percentile: Top 38%
Hidradenitis Suppurativa and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.